Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial Article

cited authors

  • Narayan, Vikram M.; Boorjian, Stephen A.; Alemozaffar, Mehrdad; Konety, Badrinath R.; Shore, Neal D.; Gomella, Leonard G.; Kamat, Ashish M.; Bivalacqua, Trinity J.; Montgomery, Jeffrey S.; Lerner, Seth P.; Busby, Joseph E.; Poch, Michael; Crispen, Paul L.; Steinberg, Gary D.; Schuckman, Anne K.; Downs, Tracy M.; Mashni, Joseph; Lane, Brian R.; Guzzo, Thomas J.; Bratslavsky, Gennady; Karsh, Lawrence I.; Woods, Michael E.; Brown, Gordon; Canter, Daniel; Luchey, Adam; Lotan, Yair; Inman, Brant A.; Williams, Michael B.; Cookson, Michael S.; Chang, Sam S.; Sankin, Alexander I.; O'Donnell, Michael A.; Sawutz, David; Philipson, Richard; Parker, Nigel R.; Yla-Herttuala, Seppo; Rehm, Dorte; Jakobsen, Jorn S.; Juul, Kristian; Dinney, Colin P. N.

Publication Date

  • July 1, 2024

webpage

published in

category

keywords

  • BCG-unresponsive bladder cancer
  • bladder cancer
  • gene therapy
  • intravesical instillation
  • nonmuscle invasive bladder cancer

start page

  • 74

end page

  • 86

volume

  • 212

issue

  • 1